These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17277317)

  • 1. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy.
    Fang CT; Chang YY; Hsu HM; Twu SJ; Chen KT; Lin CC; Huang LY; Chen MY; Hwang JS; Wang JD; Chuang CY
    QJM; 2007 Feb; 100(2):97-105. PubMed ID: 17277317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort.
    de Boer-van der Kolk IM; Sprangers MA; Prins JM; Smit C; de Wolf F; Nieuwkerk PT
    Clin Infect Dis; 2010 Jan; 50(2):255-63. PubMed ID: 20014949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
    Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
    AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
    Lloyd-Smith E; Brodkin E; Wood E; Kerr T; Tyndall MW; Montaner JS; Hogg RS
    AIDS; 2006 Feb; 20(3):445-50. PubMed ID: 16439879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
    Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).
    Kapogiannis BG; Soe MM; Nesheim SR; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
    Pediatrics; 2008 May; 121(5):e1229-39. PubMed ID: 18450865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.
    Lima VD; Hogg RS; Harrigan PR; Moore D; Yip B; Wood E; Montaner JS
    AIDS; 2007 Mar; 21(6):685-92. PubMed ID: 17413689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV infection and advanced age emerging epidemiological, clinical, and management issues.
    Manfredi R
    Ageing Res Rev; 2004 Jan; 3(1):31-54. PubMed ID: 15164725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
    Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
    HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome and prognosis factors in HIV-infected hemodialysis patients.
    Tourret J; Tostivint I; du Montcel ST; Bragg-Gresham J; Karie S; Vigneau C; Guiard-Schmid JB; Deray G; Bagnis CI
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1241-7. PubMed ID: 17699354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
    Sheng WH; Hung CC; Kao JH; Chang SY; Chen MY; Hsieh SM; Chen PJ; Chang SC
    Clin Infect Dis; 2007 Apr; 44(7):988-95. PubMed ID: 17342655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population.
    Ormaasen V; Sandvik L; Dudman SG; Bruun JN
    Scand J Infect Dis; 2007; 39(1):51-7. PubMed ID: 17366013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era.
    Chiao EY; Giordano TP; Richardson P; El-Serag HB
    J Clin Oncol; 2008 Jan; 26(3):474-9. PubMed ID: 18202423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease.
    Osborn MK; Guest JL; Rimland D
    HIV Med; 2007 Jul; 8(5):271-9. PubMed ID: 17561872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
    BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
    Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC
    Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.